Search

Your search keyword '"Peter Westervelt"' showing total 373 results

Search Constraints

Start Over You searched for: Author "Peter Westervelt" Remove constraint Author: "Peter Westervelt"
373 results on '"Peter Westervelt"'

Search Results

1. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational studyResearch in context

2. Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy

3. Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome

5. Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential

6. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001

9. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

10. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

11. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

12. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers

13. Systematic Analysis of Splice-Site-Creating Mutations in Cancer

14. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

15. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types

16. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

17. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

18. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types

19. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

20. Donor-Derived Smoldering Multiple Myeloma following a Hematopoietic Cell Transplantation for AML

21. An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

22. Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide

23. Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing.

24. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis

25. Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial

26. Data from Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression

27. Supplementary Figure from Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression

28. Supplementary Data from Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia

29. Supplementary Table from Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression

30. Supplementary Table from Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia

31. Supplementary Data from Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression

32. Supplementary Figures from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

33. Supplementary Methods from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

34. Supplementary Tables from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

35. Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study

36. NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022

37. Genomic landscape of TP53-mutated myeloid malignancies

38. Clinician Perspectives on Barriers and Enablers to Implementing an Inpatient Oncology Early Warning System: A Mixed-Methods Study

39. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

40. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022

41. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome

42. Mgta-117, an Anti-CD117-Amanitin Antibody-Drug Conjugate, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics, and Pharmacodynamics Initial Findings from a Phase 1/2 Study

43. Abstract 4342: Predictive precision medicine platform accurately predicts individual patient response to AML treatments to maximize outcomes

44. Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

45. Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic

46. Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

47. Proteomic and phosphoproteomic landscapes of acute myeloid leukemia

48. Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia

49. The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced‐intensity hematopoietic peripheral blood cell transplant – a retrospective study

50. Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia

Catalog

Books, media, physical & digital resources